Compare JEF & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JEF | RDY |
|---|---|---|
| Founded | 1968 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 9.9B |
| IPO Year | 2018 | 2001 |
| Metric | JEF | RDY |
|---|---|---|
| Price | $47.22 | $14.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $55.17 | $14.46 |
| AVG Volume (30 Days) | 2.2M | ★ 2.8M |
| Earning Date | 09-28-2026 | 10-23-2026 |
| Dividend Yield | ★ 3.38% | 0.43% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $10,823,677,000.00 | N/A |
| Revenue This Year | $16.58 | $4.57 |
| Revenue Next Year | $6.55 | $11.92 |
| P/E Ratio | $67.31 | ★ $18.67 |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $35.53 | $11.36 |
| 52 Week High | $66.60 | $15.67 |
| Indicator | JEF | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 77.25 |
| Support Level | $45.78 | $12.92 |
| Resistance Level | $49.52 | $15.67 |
| Average True Range (ATR) | 1.84 | 0.27 |
| MACD | 0.47 | 0.10 |
| Stochastic Oscillator | 40.35 | 98.62 |
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within investment banking, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.